| Clinicopathological Features | PTEN | ||||||
| Negative | Positive | Sig. | |||||
| N | % | N | % | ||||
| Age | ≤50 years-old | 25 | 47.2% | 21 | 46.7% | 0.96 | |
| >50 years-old | 28 | 52.8% | 24 | 53.3% | |||
| Tumor Size | <2 cm | 15 | 28.3% | 12 | 26.7% | 0.348 | |
| 2 - 5 cm | 31 | 58.5% | 22 | 48.9% | |||
| >5 cm | 7 | 13.2% | 11 | 24.4% | |||
| Necrosis | Absent | 31 | 58.5% | 21 | 46.7% | 0.242 | |
| Present | 22 | 41.5% | 24 | 53.3% | |||
| Tumor Grade | Grade 1 | 11 | 20.8% | 9 | 20.0% | 0.306 | |
| Grade 2 | 22 | 41.5% | 25 | 55.6% | |||
| Grade 3 | 20 | 37.7% | 11 | 24.4% | |||
| LVI* | Absent | 21 | 39.6% | 27 | 60.0% | 0.044 | |
| Present | 32 | 60.4% | 18 | 40.0% | |||
| LNM** | Negative | 7 | 13.2% | 12 | 26.7% | 0.018 | |
| Positive < 3 | 23 | 43.4% | 25 | 55.6% | |||
| Positive > 3 | 23 | 43.4% | 8 | 17.8% | |||
| Stage | Stage 1 | 5 | 9.4% | 6 | 13.3% | 0.042 | |
| Stage 2 | 23 | 43.4% | 30 | 66.7% | |||
| Stage 3 | 17 | 32.1% | 7 | 15.6% | |||
| Stage4 | 8 | 15.1% | 2 | 4.4% | |||
| TNBC*** | TNBC | 23 | 43.4% | 8 | 17.8% | 0.007 | |
| Non-TNBC | 30 | 56.6% | 37 | 82.2% | |||